AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04463134
Drug: NTM drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NTM drug treatment according to guideline and sensitivity test results
Trial: NCT00879658
Drug: BAF312
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00879658
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00866216
Drug: Azithromycin Monohydrate 600mg Tablets Geneva Pharmaceuticals
RxNorm normalized name: azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00866216
Drug: Zithromax (Azithromycin Dihydrate) 600mg Tablets Pfizer Inc.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00128063
Drug: succinylated human serum albumin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01997658
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the placebo group will receive standard perioperative care and surgery, without preoperative administration of methylprednisolone.
Trial: NCT03578042
Drug: Losartan and amlodipine and hydrochlorothiazide
RxNorm normalized name: aliskiren, amlodipine and hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: this is a fixed combination containing the 3 drugs
Trial: NCT03578042
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: any free triple combination therapy for hypertension given as 2 or 3 pills
Trial: NCT01996644
Drug: Placebo vs Setraline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01996644
Drug: Setraline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250mg DCS
Trial: NCT02205879
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02219828
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00151736
Drug: R-etodolac + chlorambucil
RxNorm normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: R-etodolac 600mg tablets + chlorambucil 2mg tablets
Trial: NCT01878695
Drug: IV/oral n-acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01637558
Drug: 8 hourly LPV/r during TB treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 hourly LPV/r during TB treatment
Trial: NCT00006126
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02658149
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.15 mg Epinephrine are injected as part of the drug cocktail
Trial: NCT00171093
Drug: valsartan + simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00874796
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken as one placebo capsule (matching in appearance to GS-9450 capsules) by mouth once daily
Trial: NCT03532178
Drug: Group A. Muscle relaxant #1: rocuronium + sugammadex; Muscle relaxant #2: succinylcholine +saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants will be randomized to start with Muscle relaxant #1 in the first study treatment, and will switch to Muscle relaxant #2 in the second study treatment period.
Trial: NCT00332189
Drug: sapropterin dihydrochloride
RxNorm normalized name: Sapropterin Dihydrochloride
DrugBank: Sapropterin (DB00360)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 5-20mg/kg/day orally, dose may be adjusted up or down as needed at the discretion of the investigator in increments of 5mg/kg/day.
Trial: NCT00913653
Drug: LCZ696
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00867282
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-00241939 750ug using inhaler A
Trial: NCT00867282
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-00241939 750ug using inhaler B
Trial: NCT00395148
Drug: rHDL
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01231516
Drug: GSK1349572 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive placebo tablet once daily
Trial: NCT02179918
Drug: MK-3475
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg q3wks, IV
Trial: NCT00690235
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180mg subcutaneous injections, twice daily
Trial: NCT00343798
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03451292
Drug: Albutein 20% Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Within 96 hours after discharge and following randomization, subjects will receive the first Albutein 20% infusion at the dose of 1.5 g/kg body weight (maximum 100 grams per subject). Thereafter, subjects will receive Albutein 20% infusions at the dose of 1.5 g/kg body weight (maximum 100 grams per subject) every 10 ± 2 days for the rest of the study (up to a maximum of 12 months). Subjects in this treatment group will also receive SMT.
Trial: NCT02253940
Drug: BILR 355 - Treatment B (new tablet formulation)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02253940
Drug: BILR 355 - Treatment C (new capsule formulation)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02253940
Drug: BILR 355 - Treatment E (new capsule formulation)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00003261
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03366246
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: according randomized this side received placebo or active product
Trial: NCT01631942
Drug: NNC172-2021
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as subcutaneous (s.c., under the skin) injections every other day for two weeks.~Escalation to next dose level is based on a safety evaluation.
Trial: NCT03424135
Drug: Naproxen sodium and diphenhydramine hydrochloride soft capsules
RxNorm normalized name: naproxen and diphenhydramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 capsules)
Trial: NCT03424135
Drug: Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve PM, BAY98-7111)
RxNorm normalized name: naproxen and diphenhydramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 tablets)
Trial: NCT04701502
Drug: Standard Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care for COVID-19
Trial: NCT03935828
Drug: Oral versus topical antibioitics
RxNorm normalized name: Betadine Antibiotic Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previously described in two arms
Trial: NCT02775617
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will be offered treatment for both yaws and scabies either in parallel or in sequence. Azithromycin will be offered as single dose of 30mg/kg, max 2G.
Trial: NCT00774111
Drug: GSK1349572
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1349572 50 mg in combination with Etravirine
Trial: NCT01836653
Drug: l-LV
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
Trial: NCT01845220
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80% acetone
Trial: NCT01096095
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powdered placebo in sachets containing each 3g. At the start of the study, the dose will be 15g/day (five sachets).
Trial: NCT01441778
Drug: NSS nasal irrigation salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nasal irrigation twice daily for 4 weeks period
Trial: NCT03675178
Drug: Anerning particle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anerning particle ,1 bag/time,3 times/ day, +ceftriaxone sodium,50mg/kg/time, 1 time/day, the total amount per day does not exceed 2g，for 10 days.When the condition is cured, stop the medicine at any time.
Trial: NCT01441778
Drug: BHS nasal irrigation salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nasal irrigation twice daily for 4 weeks period
Trial: NCT03675178
Drug: control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anerning particle placebo ,1 bag/time,3 times/ day, +ceftriaxone sodium,50mg/kg/time, 1 time/day, the total amount per day does not exceed 2g，for 10 days.When the condition is cured, stop the medicine at any time.
Trial: NCT00789061
Drug: Proton pump inhibitor
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dosage/day/year
Trial: NCT00510367
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg/m\^2 By Vein On Day 1
Trial: NCT00510367
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m\^2 By Vein Over 72 Hours
Trial: NCT02788591
Drug: Proton Pump Inhibitor (PPI) Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will take a proton pump inhibitor (PPI) of their choice (Omeprazole, Esomeprazole, Pantoprazole, or Lansoprazole) 2 times a day for 8 weeks.
Trial: NCT00555347
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02509403
Drug: Essential oils infused Perineal Hygiene wipe
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each participant will be asked to complete a treatment period of one month's duration. At the start of the study, the participants will be asked to fill-out a baseline questionnaire and will be given a month's supply of the perineal hygiene towel with instructions about its use. At day 15, 30 and 45 follow-ups will be conducted.
Trial: NCT00757367
Drug: TI Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 60-U dose of TI Inhalation Powder before the bronchoscopy. Cohort 1 will undergo bronchoscopies at 30 minutes and again at 6 hours after the 60-U dose inhalation of TI Inhalation Powder. Cohort 2 bronchoscopies will occur at 4 hours and again at 8 hours after TI Inhalation Powder. The need to run and the timepoints for bronchoscopies for Cohort 3 will be determined based on the results from Cohort 1 and 2. All subjects will undergo 2 bronchoscopies at Visit 2.
Trial: NCT02042443
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT02042443
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02203123
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02042443
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00133692
Drug: Verapamil SR/Trandolapril/Hydrochlorothiazide (HCTZ)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04677868
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methylprednisolone 1 mg/kg/day MTX (10 mg/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was less than grade II;
Trial: NCT02138916
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo subcutaneously on study week 0 until study week 48 inclusive
Trial: NCT03848481
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral solution contains matching excipients.
Trial: NCT00002790
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03310463
Drug: ETX2514SUL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of up to 1000 mg ETX2514 and 1000 mg sulbactam given by concurrent 3-hr IV infusion
Trial: NCT00084578
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02366377
Drug: SHR3824
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02366377
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01860196
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01192178
Drug: FLOVENT™ DISKUS™ 100 mcg BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLOVENT™ DISKUS™ 100 mcg, one inhalation twice daily (BID) from the DISKUS device from randomization through the end of study (week 16).
Trial: NCT01192178
Drug: ADVAIR™ DISKUS™ 100/50 mcg BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADVAIR™ DISKUS™ 100/50 mcg is a combination product containing a 100 mcg fluticasone propionate and a 50 mcg salmeterol. One inhalation from the DISKUS device twice daily (BID) from randomization through end of study (week 16).
Trial: NCT01943617
Drug: Thymosin-α
RxNorm normalized name: chymosin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-viral and antitherapy
Trial: NCT03180710
Drug: BioChaperone® Combo 75/25 at 0.6 U/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of BioChaperone® Combo 75/25 at 0.6 U/kg
Trial: NCT03180710
Drug: BioChaperone® Combo 75/25 at 0.8 U/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of BioChaperone® Combo 75/25 at 0.8 U/kg
Trial: NCT03180710
Drug: BioChaperone® Combo 75/25 at 1.0 U/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of BioChaperone® Combo 75/25 at 1.0 U/kg
Trial: NCT03180710
Drug: Humalog® Mix25 at 0.8 U/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of Humalog® Mix25 at 0.8 U/kg
Trial: NCT00576511
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo o.d.
Trial: NCT04433104
Drug: drug therapy according to Vietnamese MOHS procedure
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol, Terbutaline
Trial: NCT01535014
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo either (2 tablets 3 times daily) or~(1 tablet 6 times daily)
Trial: NCT03507374
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to be administered subcutaneously every 2 weeks identical to active drug (alirocumab)
Trial: NCT02208154
Drug: Selective Digestive Decontamination (SDD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SDD consists of both:~* SOD (described elsewhere)~* AND 10 ml of an enteric suspension containing 100 mg colistin, 80 mg tobramycin and nystatin 2 x 10\^6 i.u, to be administered via the nasogastric tube.~The combination is administered 4 times daily (Unlike in previous studies, systemic antibiotics are not a part of SDD)
Trial: NCT00485160
Drug: Continuous indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00485160
Drug: ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00068523
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cyclophosphamide IV over 1 hour on days -3 to -2
Trial: NCT02188160
Drug: KPI-121
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KPI-121 drug product will be supplied as 0.25% as a suspension in identically packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
Trial: NCT02188160
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to placebo control arms will receive the same bottles containing all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
Trial: NCT02489513
Drug: [14C]-AG-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labeled investigational drug
Trial: NCT00009841
Drug: DC-cholesterol liposome
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00294554
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, taken by mouth, will be titrated from 5mg a day to 20mg a day over 4 weeks. The subject will remain on 20mg (10mg twice a day) through week 24 unless unable to tolerate. The dose will be decreased as needed.
Trial: NCT00862355
Drug: SPARC147609
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT00862355
Drug: Reference147609
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT00747877
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally
Trial: NCT00916578
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: During 5-7 weeks of radiation therapy, 825 mg/m2 (pills) by mouth, 2 times a day, about 12 hours apart, 30 minutes after eating food and about 2 hours before radiation therapy.
Trial: NCT01856166
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02986334
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects enrolled in the active treatment arm will receive 500mg of Naproxen prescribed twice daily, once in the morning and evening.
Trial: NCT02986334
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects enrolled in the inactive treatment arm will receive two prescriptions, however, there are no active ingredients and are intended to look identical to the active treatment. Therefore, subjects will be instructed exactly the same way as if they were ingesting the active treatment.
Trial: NCT01012843
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral Placebo tablets two times a day for 10 days
Trial: NCT00480584
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Level 1: 500 mg/m\^2; Level 2: 825 mg/m\^2; Level 3: 1000 mg/m\^2; Level 4: 1250 mg/m\^2
Trial: NCT02987868
Drug: Placebo first day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A non-active orally administered supplement of the proprietary amino acid derivative
Trial: NCT02987868
Drug: Placebo second day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A non-active orally administered supplement of the proprietary amino acid derivative
Trial: NCT01727622
Drug: FDG-PET
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diagnostic: FDG-PET imaging to examine neuronal health
Trial: NCT00184821
Drug: adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01093521
Drug: 100 mg/m2 dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 day infusion of gallium nitrate (IV Ganite®) at a dose of 100 mg/m2/day
Trial: NCT00982215
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilot study of Pharmacology Paracetamol administered per-oral mucosa PMB. Crossover study, double-blind, randomized, controlled versus placebo.
Trial: NCT00744185
Drug: placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 days-placebo treatment : 3 mg/kg 15 days + 4 mg/kg 15 days
Trial: NCT03092895
Drug: FOLFOX4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects receive FOLFOX4 treatment every 2 weeks
Trial: NCT01092624
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There will be a two-week pessary run-in prior to randomization. If the subject completes the run-in period with no adverse reactions to the pessary, she will come in to the office for a randomization visit. She will be randomized to receive either 5 mg/day (one 5 mg tablet QD) of placebo or 5 mg/day (QD) of solifenacin for 12 weeks. At the end of week 6, patients will be assessed in the office. A standardized medication response questionnaire will be used to assess each subject's response to either the placebo or the solifenacin 5 mg. If the response is not adequate, the dose will be increased. Women whose symptoms have not improved since baseline will have their medication or placebo doses increased to 10 mg daily.
Trial: NCT02656043
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03406260
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT00353379
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will take placebo for 6 weeks.
Trial: NCT02237079
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily placebo tablet
Trial: NCT03088059
Drug: standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care